AbbVie Australia is a biopharmaceutical company whose mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. Science and innovation are the cornerstones of the business and each day 320 Australian employees dedicate their time to making a remarkable impact on its 31,500+ patients’ lives.
AbbVie sees a future of possibility, where health is in reach and patient lives are improved. AbbVie operates in a highly competitive environment, and often in some of the markets that it is present in there might be as many as 10 or 11 medicines that are used in the same therapeutic area.
The AbbVie mission is that through innovation and collaboration it can deliver a remarkable impact to patients. The core of this impact is how it can drive innovative ideas and opportunities that will keep AbbVie ahead of the game. AbbVie defines innovation as “Change that Adds Value”. At AbbVie, Innovation is critical to the way it does business, so much so that every employee undergoes Innovation training as part of their onboarding.
AbbVie wanted to enable patients to travel anywhere around the world, which required a solution that met the needs of long haul travel (+30hrs travel time), so the team applied the innovation process to the patient problem that long-haul travel was extremely problematic for patients taking HUMIRA.
During the innovation process they tested existing solutions within the market place, and uncovered that nothing that was available met the standards required, so the AbbVie team worked with an industry leading cold chain management supplier to design and manufacture a long-haul travel case. With a manufacturing partner a prototype was developed to enable user testing. Following user feedback, the prototype was further improved to ensure its weight was reduced, packing instructions were simplified, its look and feel was improved and some additional features were added to ultimately improve user experience.
The 36-hour travel case is now approved for use not just in Australia, but in all 75 countries that AbbVie operates in and allows patients to transport at least one-month’s supply of its medicine. Demand has exceeded expectations, a contributing success factor. In fact, usage to date has now exceeded 1,000 units, validating the need to support patients further by maintaining the quality use of AbbVie’s medicine, and enabling a greater quality of life.
Maintaining the cold chain ensures patients will have enough supply of their medication through the duration of their travels. This now allows patients to consider travel options that may not have been available to them before. This innovative, low-cost solution benefits patients by allowing them to travel with larger quantities of product without having to constantly worry about temperature control. It also gives doctors confidence that its medicine can now be transported long distances safely and effectively and demonstrates that alternative, non-validated solutions no longer need to be considered.